Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02659241 · ClinicalTrials.gov registry record · Early Phase 1
Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Early Phase 1 study of Advanced Ovarian Carcinoma and Ovarian High Grade Serous Adenocarcinoma, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Early Phase 1
- Development phase
- 38
- Enrollment target
- 8
- Study locations
NCT02659241 is a Early Phase 1 study of Advanced Ovarian Carcinoma and Ovarian High Grade Serous Adenocarcinoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 38 participants, below the 126-participant average among 10 other Advanced Ovarian Carcinoma trials with a reported enrollment target (70% lower). The trial reports 8 study locations across 2 states.
The verdict
NCT02659241, a Early Phase 1 study of Advanced Ovarian Carcinoma and Ovarian High Grade Serous Adenocarcinoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 38 participants
- Enrollment target
- 8
- Study locations
Study Summary
This pilot early phase I trial studies how adavosertib affects the tumor deoxyribonucleic acid (DNA) of patients undergoing surgery for high grade (fast growing or aggressive) ovarian, fallopian tube, or primary peritoneal cancer that has spread to other places in the body (advanced). Certain characteristics in the DNA of these patients may affect how well they respond to treatment. Learning how adavosertib affects DNA in tumor cells may help doctors plan effective treatment.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Adavosertib
Study Locations (8)
Texas
- MD Anderson in The Woodlands - Conroe
- Memorial Hermann Memorial City Medical Center - Houston
- M D Anderson Cancer Center - Houston
- The Woman's Hospital of Texas - Houston
- MD Anderson West Houston - Houston
- MD Anderson League City - League City
- MD Anderson in Sugar Land - Sugar Land
Oregon
- OHSU Knight Cancer Institute - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2016-02-04 |
| Est. Completion | 2026-12-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02659241
The ClinicalTrials.gov registry entry for NCT02659241 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 126-participant average among 10 other Advanced Ovarian Carcinoma trials with a reported enrollment target (70% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Advanced Ovarian Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02659241 reports 8 study locations spanning 2 distinct geographic areas - top geographies include Texas, Oregon.
Frequently Asked Questions
What is clinical trial NCT02659241 about?
NCT02659241 is a clinical study titled "Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer". This pilot early phase I trial studies how adavosertib affects the tumor deoxyribonucleic acid (DNA) of patients undergoing surgery for high grade (fast growing or aggressive) ovarian, fallopian tube, or primary peritoneal cancer that has spread to other places in the body (advanced). Certain charac...
What is the current status of trial NCT02659241?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 38 participants. The study started on 2016-02-04. Estimated completion is 2026-12-31.
What conditions does trial NCT02659241 study?
This clinical trial studies the following conditions: Advanced Ovarian Carcinoma, Ovarian High Grade Serous Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Advanced Fallopian Tube Carcinoma.
What interventions are being tested in trial NCT02659241?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Adavosertib (DRUG).
Who is sponsoring clinical trial NCT02659241?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02659241 being conducted?
This trial has 8 study locations across Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Ovarian Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy
RECRUITING · Early Phase 1
-
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
RECRUITING · Phase 2
-
REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
RECRUITING · NA
-
Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial
RECRUITING · Phase 2
-
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
RECRUITING · Phase 1
-
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
RECRUITING · Phase 3
Explore more on PlainTrial
Advanced Ovarian Carcinoma
All registered trials for this condition
Ovarian High Grade Serous Adenocarcinoma
All registered trials for this condition
Oregon
All trials with a study site in Oregon
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.